Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis
Author:
Hu Ke1, Jiang Pin2, song Bing3, Hou Ya4, Gu Qianyu4, Guo Meng4, Peng Ningxin3, Chen Jiayu3, Zhao Jinxuan4, Chen Haiting3, Xie Jun1
Affiliation:
1. The Affiliated Drum Tower Hospital of Nanjing Medical University, Jiangsu,Nanjing, 210008, China 2. Department of General Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, 230022,China 3. Department of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, 230022, China 4. Department of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, MOE Key Laboratory of Model Animal for Disease Study, Nanjing University, Jiangsu,
Abstract
Abstract
Lipopolysaccharide induces sepsis in vivo, with a significant proportion of septic patients progressing to septic cardiomyopathy. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to have cardioprotective effects, with reports indicating a reduction in myocardial ischemia-reperfusion injury through the attenuation of ferroptosis. However, the role of ferroptosis-induced myocardial injury in the context of LPS-induced sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced iron-overload cardiac injury. Our results indicate that dapagliflozin inhibits the translation of key proteins associated with ferroptosis, including GPX4, FTH1, and SLC7A11, while reducing the transcription of lipid peroxidation-related mRNAs PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1. Additionally, both compounds alleviate potential mitochondrial membrane damage. Furthermore, dapagliflozin has been shown to mitigate LPS-induced cardiac injury burden. Based on these findings, we conclude that dapagliflozin can alleviate LPS-induced iron dysregulation-mediated cardiac dysfunction, expanding the clinical indications for SGLT2 inhibitors.
Publisher
Research Square Platform LLC
Reference47 articles.
1. Antonucci, E., Fiaccadori, E., Donadello, K., Taccone, F.S., Franchi, F., Scolletta, S., 2014. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care 29, 500–511. 2. Bajic, V.P., Van Neste, C., Obradovic, M., Zafirovic, S., Radak, D., Bajic, V.B., Essack, M., Isenovic, E.R., 2019. Glutathione "Redox Homeostasis" and Its Relation to Cardiovascular Disease. Oxidative medicine and cellular longevity 2019, 5028181. 3. Belch, J.J., Bridges, A.B., Scott, N., Chopra, M., 1991. Oxygen free radicals and congestive heart failure. Br Heart J 65, 245–248. 4. Chen, X., Li, J., Kang, R., Klionsky, D.J., Tang, D., 2021. Ferroptosis: machinery and regulation. Autophagy 17, 2054–2081. 5. Chen, Y.R., Zweier, J.L., 2014. Cardiac mitochondria and reactive oxygen species generation. Circulation research 114, 524–537.
|
|